Blar i NHH Brage på forfatter "Straume, Odd Rune"
-
Access regulation and cross-border mergers : is international coordination beneficial?
Lommerud, Kjell Erik; Olsen, Trond E.; Straume, Odd Rune (Working paper, Working paper, 2005-06)The international integration of regulated markets poses new challenges for regulatory policy. One question is the implications that the overall international regulatory regime will have for cross-border and/or domestic ... -
Access regulation and cross-border mergers : is international coordination beneficial?
Lommerud, Kjell Erik; Olsen, Trond E.; Straume, Odd Rune (Discussion paper, Working paper, 2005-04)The international integration of regulated markets poses new challenges for regulatory policy. One question is the implications that the overall international regulatory regime will have for cross-border and/or domestic ... -
Are pharmaceuticals still inexpensive in Norway? : a comparison of prescription drug prices in ten European countries
Brekke, Kurt Richard; Holmås, Tor Helge; Straume, Odd Rune (Report, Research report, 2010-05)In this report we compare prices of pharmaceuticals between Norway and nine Western European countries (Austria, Belgium, Denmark, Finland, Germany, Ireland, the Netherlands, Sweden and United Kingdom). The purpose is to ... -
Can competition reduce quality?
Brekke, Kurt Richard; Siciliani, Luigi; Straume, Odd Rune (Discussion paper;9/2012, Working paper, 2012-03)We study the effect of competition on quality in markets such as health care, long-term care and education, when providers choose both prices and quality in a setting of spatial competition. We offer a novel mechanism ... -
Comparing pharmaceutical prices in Europe : a comparison of prescription drug prices in Norway with nine Western European countries
Brekke, Kurt Richard; Holmås, Tor Helge; Straume, Odd Rune (Report;2011:11, Research report, 2011-10)In this report we compare prices of pharmaceuticals between Norway and the following nine Western European countries: Austria, Belgium, Denmark, Finland, Germany, Ireland, the Netherlands, Sweden and United Kingdom. We use ... -
Competing with precision: incentives for developing predictive biomarker tests
Brekke, Kurt R.; Dalen, Dag Morten; Straume, Odd Rune (SAM DP;06/2022, Working paper, 2022-03)We study the incentives of drug producers to develop predictive biomarkers, taking into account strategic interaction between drug producers and health plans. For this purpose we develop a two-dimensional spatial framework ... -
Competition and physician behaviour: Does the competitive environment affect the propensity to issue sickness certificates?
Brekke, Kurt R.; Holmås, Tor Helge; Monstad, Karin; Straume, Odd Rune (DP SAM;3, Working paper, 2017)Competition among physicians is widespread, but compelling empirical evidence on the impact on service provision is limited, mainly due to lack of exogenous variation in the degree of competition. In this paper we exploit ... -
Competition and physician behaviour: Does the competitive environment affect the propensity to issue sickness certificates?
Straume, Odd Rune; Brekke, Kurt R.; Holmås, Tor Helge; Monstad, Karin (Working paper, 2018-09)Competition among physicians is widespread, but compelling empirical evidence on its impact on service provision is limited, mainly due to endogeneity issues. In this paper we exploit that many GPs, in addition to own ... -
Competition and quality in regulated markets with sluggish demand
Brekke, Kurt Richard; Cellini, Roberto; Siciliani, Luigi; Straume, Odd Rune (Discussion paper, Working paper, 2008-08)We investigate the effect of competition on quality in regulated markets (e.g., health care, higher education, public utilities), using a Hotelling framework, in the presence of sluggish demand. We take a differential game ... -
Competition and quality in regulated markets: a differential-game approach
Brekke, Kurt Richard; Straume, Odd Rune; Siciliani, Luigi; Cellini, Roberto (Discussion paper, Working paper, 2008-02)We investigate the effect of competition on quality in regulated markets (e.g., health care, higher education, public utilities) taking a differential game approach, in which quality is a stock variable. Using a Hotelling ... -
Competition and waiting times in hospital markets
Brekke, Kurt Richard; Siciliani, Luigi; Straume, Odd Rune (Discussion paper, Working paper, 2007-03)This paper studies the impact of hospital competition on waiting times. We use a Salop-type model, with hospitals that differ in (geographical) location and, potentially, waiting time, and two types of patients; high-benefit ... -
Do Treatment Decisions Depend on Physicians` Financial Incentives?
Brekke, Kurt R.; Holmås, Tor Helge; Karin, Monstad; Straume, Odd Rune (Discussion paper;15/15, Working paper, 2015-07)We study whether and how physicians respond to financial incentives, making use of detailed register data on the health-care services provided to patients by general practitioners (GPs) in Norway over a six-year period ... -
Does Reference Pricing Drive Out Generic Competition in Pharmaceutical Markets? Evidence from a Policy Reform
Brekke, Kurt R.; Canta, Chiara; Straume, Odd Rune (Discussion paper;11/15, Working paper, 2015-06)In this paper we study the impact of reference pricing (RP) on entry of generic firms in the pharmaceutical market. For given prices, RP increases generic firms' expected profit, but since RP also stimulates price ... -
Downstream merger with upstream market power
Lommerud, Kjell Erik; Straume, Odd Rune; Sørgard, Lars (Working Paper, Working paper, 2002-12)We examine how a downstream merger affects input prices and, in turn, the profitability of a such a merger under Cournot competition with differentiated products. Input suppliers can be interpreted as ordinary upstream ... -
Er legemidler billig i Norge? : en sammenligning av priser på reseptpliktige legemidler mellom Norge og ni vest-europeiske land
Brekke, Kurt Richard; Holmås, Tor Helge; Straume, Odd Rune (Rapport, Research report, 2008-05)I denne rapporten sammenlignes priser på legemidler i Norge med priser på tilsvarende legemidler i følgende ni referanseland: Belgia, Danmark, Finland, Irland, Nederland, Storbritannia, Sverige, Tyskland og Østerrike. ... -
Er legemidler fremdeles billig i Norge? : en sammenligning av priser på reseptpliktige legemidler mellom Norge og ni vest-europeiske land
Brekke, Kurt Richard; Holmås, Tor Helge; Straume, Odd Rune (Rapport, Research report, 2009-04)Rapporten sammenligner priser på legemidler i Norge med priser på tilsvarende legemidler i følgende ni referanseland: Belgia, Danmark, Finland, Irland, Nederland, Storbritannia, Sverige, Tyskland og Østerrike. Utvalget ... -
Good jobs, bad jobs and redistribution
Lommerud, Kjell Erik; Sandvik, Bjørn; Straume, Odd Rune (Working Paper, Working paper, 2001-08)We analyse the question of optimal taxation in a dual economy, when the government is concerned about the distribution of labour income. Income inequality is caused by the presence of sunk capital investments, which creates ... -
Horizontal mergers and product quality
Brekke, Kurt Richard; Siciliani, Luigi; Straume, Odd Rune (Discussion paper;4/2014, Working paper, 2014-02)Using a spatial competition framework with three ex ante identical firms, we study the effects of a horizontal merger on quality, price and welfare. The merging firms always reduce quality. They also increase prices if ... -
Hospital competition and quality with regulated prices
Brekke, Kurt Richard; Straume, Odd Rune; Siciliani, Luigi (Discussion paper, Working paper, 2008-02)We analyse the effect of competition on quality in hospital markets with regulated prices, considering both the effect of free patient choice (monopoly versus competition) and increased competition through lower transportation ... -
Hospital competition in the national health service : evidence from a patient choice reform
Brekke, Kurt R.; Canta, Chiara; Siciliani, Luigi; Straume, Odd Rune (Arbeidsnotat;2018/10, Working paper, 2018-12)We study the impact of exposing hospitals in a National Health Service (NHS) to non-price competition by exploiting a patient choice reform in Norway in 2001. The reform facilitates a di§erence-in-di§erence research ...